Alector Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last twelve months. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Alector stock.
View analyst ratings for Alector or view top-rated stocks.

6 brokers have issued 1-year price objectives for Alector's stock. Their ALEC stock forecasts range from $6.00 to $57.00. On average, they predict Alector's stock price to reach $29.86 in the next twelve months. This suggests a possible upside of 170.9% from the stock's current price.
View analysts' price targets for Alector or view top-rated stocks among Wall Street analysts.

Alector's stock was trading at $20.65 at the beginning of 2022. Since then, ALEC stock has decreased by 46.6% and is now trading at $11.02.
View the best growth stocks for 2022 here.

Alector is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Alector.

Alector, Inc. (NASDAQ:ALEC) issued its quarterly earnings results on Thursday, November, 4th. The company reported $1.49 EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $1.95. The company earned $182.41 million during the quarter, compared to analyst estimates of $407.41 million. Alector had a negative net margin of 12.65% and a negative trailing twelve-month return on equity of 10.57%.
View Alector's earnings history.

4 employees have rated Alector CEO Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among Alector's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Alector include Vir Biotechnology (VIR), Abcam (ABCM), Beam Therapeutics (BEAM), Bavarian Nordic A/S (BVNRY), Fate Therapeutics (FATE), Twist Bioscience (TWST), BioCryst Pharmaceuticals (BCRX), Relay Therapeutics (RLAY), Iovance Biotherapeutics (IOVA), Krystal Biotech (KRYS), Allogene Therapeutics (ALLO), Immunocore (IMCR), ImmunityBio (IBRX), Revolution Medicines (RVMD) and Recursion Pharmaceuticals (RXRX).
View all of ALEC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO).

(ALEC) raised $177 million in an initial public offering on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO.

Alector trades on the NASDAQ under the ticker symbol "ALEC."

Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALEC stock can currently be purchased for approximately $11.02.

Alector (NASDAQ:ALEC) has a market capitalization of $918.26 million and generates $207.09 million in revenue each year. The company earns $-36.33 million in net income (profit) each year or ($0.420010) on an earnings per share basis.

Alector employs 208 workers across the globe.

Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The official website for Alector is www.alector.com. The company can be reached via phone at (415) 231-5660 or via email at ir@alector.com.